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Background: Infections which complicate rheumatic diseases such as Rheumatoid Arthritis (RA) and
Spondyloarthropathy (SpA) (Psoriatic Arthritis [PA] and Ankylosing Spondylitis [AS]), may cause significant morbidity
and mortality. However, among the studies on the incidence rate (IR) of infections in such patients, very few have
involved controls and the results have been controversial, probably due to methodological difficulties.
To estimate infection rates in RA and SpA patients under disease-modifying anti-rheumatic drugs (DMARDs),
corticosteroids (CS) and tumor necrosis factor (TNF)α antagonists, alone or combined, a single-centre retrospective
observational cohort study has been performed.
Patients and methods: Incidence rates/100 patient-years of any infections were evaluated in RA and SpA outpatients
observed in the period November 1, 2003 through December 31, 2009 and stratified according to therapy. Infection
incidence rate ratios (IRR) were calculated using Poisson regression models which adjusted for demographic/clinical
characteristics of the patients.
Results: Three hundred and thirtyone infections [318 (96.1%) non-serious and 13 (3.9%) serious] have been
registered among 176 of the 341 patients (52%). The IR/100 patient-years of all infections was 36.3 ranging from
12.4 (DMARDs + CS) to 62.7 (anti-TNFα + CS). The most frequent infection site was respiratory tract, and bacteria were
responsible for three quarters of all infections. In the multivariate analysis, adding anti-TNFα to DMARDs doubled the
IRR compared to DMARDs alone, anti-TNFα + CS significantly tripled it, whereas anti-TNFα + CS + DMARDs only
increased the risk 2.5 times. The degree of disease activity was strongly and significantly associated with the infection
risk (severe or moderate versus mild, IRR = 4). Female sex was significantly associated with increased infection risk,
while duration of disease and anti-influenza vaccination were protective, the latter even for cutaneous/soft-tissue
(mainly herpetic) infections.
Conclusion: The combination anti-TNFα with CS was found to be the most pro-infective treatment, whereas DMARDs
alone were relatively safe. Physicians, therefore, should be aware that there may be an increased risk of infection when
using anti-TNFα and CS therapy together. Anti-influenza vaccination appears to provide broad protection, adding
evidence to support its use in these patients, and deserves further study.
Keywords: Rheumatoid Arthritis, Spondyloarthropathy, Infection risk, anti-TNFα, DMARDs, Corticosteroids* Correspondence: raffaele.damelio@uniroma1.it
†Equal contributors
1Department of Clinical and Molecular Medicine, “Sapienza” University of
Rome, S. Andrea University Hospital, Via di Grottarossa 1039, 00189 Rome,
Italy
Full list of author information is available at the end of the article
© 2014 Germano et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Germano et al. Journal of Translational Medicine 2014, 12:77 Page 2 of 10
http://www.translational-medicine.com/content/12/1/77Infections which complicate rheumatic diseases such
as Spondiloarthropathy (SpA) (Psoriatic Arthritis [PA] and
Ankylosing Spondylitis [AS]) and Rheumatoid Arthritis
(RA), may cause significant morbidity and mortality [1-3].
However, among the studies on the incidence rate (IR) of
infections in such patients, very few have involved controls
and the results have been controversial, probably due to
methodological differences.
A Dutch group found no significant difference be-
tween RA patients and controls regarding the IR of in-
fections [4]. In contrast, other authors have noted an
increased infection risk [5-7]; in particular, Doran et al.
[7] in 609 US RA patients found a doubled risk of devel-
oping an objectively confirmed infection compared with
a sample of 609 age- and sex-matched controls without
RA. Contradictory results are probably, at least in part, a
consequence of the different events studied, including
overall, non-serious, serious or opportunistic infections,
different patient groups or different statistical parame-
ters [8]. Moreover, the high statistical power obtained
from large patient populations is frequently counterba-
lanced by possible bias linked to the scarce availability of
detailed clinical information [9,10], which may eventu-
ally compromise the outcome. Finally, also the type of
study, randomized controlled trial or observational study,
may make a difference, particularly in relation to the
patient selection criteria. Although, to the best of our
knowledge, studies comparing the infection risk between
RA and SpA patients are lacking, the risk in the second
patient group seems to be low [11].
More recently, with the introduction of biologics in
therapy, infection susceptibility has increased. Conse-
quently, some studies, have drawn attention not only
to the disease itself, but also to immune suppression
induced by corticosteroids (CS), non biological disease-
modifying anti-rheumatic drugs (DMARDs) and biologics.
Data on infection risk generally show that DMARDs
(mainly methotrexate [MTX]), are relatively safe, whereas
there is little debate on the capacity of CS to increase
infection susceptibility [12]. Doran et al. analyzing RA pa-
tients, mainly treated with DMARDs and CS, did not find
an increased infection risk associated with DMARDs,
whereas in a multivariate analysis they identified CS as a
predictor of infections [13]. Lacaille et al. [9] demonstrated
an increased risk of mild and serious infections in RA pa-
tients taking CS, but no increase for DMARDs. Partially in
contrast, Bernatsky et al., in RA patients found the highest
risk of serious infections with CS and immunosuppressive
DMARDs [14]. Although several studies have documented
the effectiveness of anti-tumor necrosis factor (TNF)α,
conflicting results on the possible increase in the number
and/or severity of infections have also been reported. In
placebo-controlled trials evaluating each one of three
TNFα blockers for RA patients, the rate of any infectionsdid not exceed the rate in the placebo group [15-17], while
data from a meta-analysis suggest an increased risk
for serious infections [18]. Indeed, data from the British
Biologics Register estimated a 2-fold increased risk of
serious infections [19] and a recent review [20] reported a
4-fold increased risk of serious bacterial infections in RA
patients. In the analysis of the RABBIT German Registry,
the risk of serious infections was directly related to the
dose of CS, especially when associated with TNFα.
The aim of this retrospective observational cohort study
was to evaluate the impact of DMARDs, CS and the three
TNFα antagonists licensed in Italy between 2001 and 2005,
in mono or combination therapy, on non-serious and ser-
ious infections in RA and SpA patients.
Patients and methods
All the RA and SpA (PA and AS) outpatients observed
at the Immuno-rheumatology Division of the S. Andrea
University Hospital, Rome, during the period November
2003-December 2009 were evaluated and IRs/100 patient-
years of non-serious and serious infections were cal-
culated. RA, PA and AS were diagnosed on the basis
of the recommendations of the 1987 American College
of Rheumatology [21], Moll and Wright [22] and modi-
fied New York criteria [23], respectively. Patients were
checked at 3-month intervals and stratified according to
the type of therapy: DMARDs alone, DMARDs + CS,
anti-TNFα alone, anti-TNFα + CS, anti-TNFα + DMARDs
and anti-TNFα + DMARDs + CS. The anti-TNFα therapy
was introduced following accepted guidelines [Disease
Activity Score (DAS) on 44 joints > 3.7 or Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI) > 4] in the
absence of contraindications. In particular, patients were ex-
cluded in the presence of any active infection after screening
with the tuberculin skin test (TST), chest radiograph and
hepatitis B (HBV) and C (HCV) viral markers. TST positive
patients underwent microbiological and further radiological
assessment, in order to exclude active overt disease. In
patients without active disease, isoniazid was administered
for at least 2 months before starting biological therapy and
continued for a total of 6–9 months [24,25]. HBV active
and inactive carriers underwent an anti-viral therapy or
prophylaxis, respectively, whereas occult carriers were
treated with biologics. In this case, viral markers including
DNA levels and hepatic function were monitored through-
out therapy [26,27]. HCV-antibody positivity was not con-
sidered a cause of exclusion, but, in the case of HCV
viremia, specific anti-viral treatment before and quantitative
viral evaluation and serum alanine aminotransferase moni-
toring after biological therapy was suggested [27,28].
The Ethics Committee of the S. Andrea University
Hospital approved the study (approval number 132/2012).
All infections occurring during treatment were noted
either at planned or at patient solicited medical checks
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but only orally, solicited to immediately notify any pos-
sible adverse event occurring during the treatment, espe-
cially infections. These infections were actively looked for
and diagnosed on the basis of clinical assessment and re-
sponse to anti-infective treatment. Only the infections re-
ported in the medical records collected during outpatient
visits were considered. Moreover, they were classified ac-
cording to demonstrated (by imaging and/or microbio-
logical analyses) or presumed etiology (bacterial, viral
and/or fungal) and site (respiratory, uro-genital, gastro-
intestinal, skin and soft tissue, bone and joints). Among
respiratory infections, influenza-like-illness (ILI) episodes
have been identified on the basis of the following clin-
ical parameters: “acute respiratory tract infection and
fever ≥ 38°C accompanied by systemic or respiratory
symptoms” [29]. Moreover infections were defined as ei-
ther serious when life-threatening, requiring hospitalization
and/or intravenous anti-infective treatment, or non-serious
when only requiring a physician visit and/or use of
not intravenous anti-infective medications. Comorbidi-
ties (diabetes mellitus, leukopenia, chronic obstructive
pulmonary disease [COPD]) and smoking status, were
considered. Disease activity was classified as mild, moder-
ate and severe when DAS was <2.4, 2.4-3.7, >3.7 and
BASDAI 1–3, 4–7 and 8–10, respectively. Anti-influenza
and anti-pneumococcal vaccinations, only administered to
patients with mild/moderate disease activity in order to
prevent any flare up, were recorded.
Statistical analysis
Proportions were calculated for the demographic and
clinical characteristics of all patients. For important clin-
ical characteristics, IRs, defined as the number of ob-
served events (infections)/100 patient-years of follow-up,
were calculated, to estimate the risk of infection in the
different groups. Also, Incidence Rate Ratios (IRR) and
their statistical significance were obtained from Poisson
regression analysis. In crude analyses, statistical differ-
ences were evaluated by χ2 tests and Fisher’s exact test.
Variables considered as potential confounders or inde-
pendent predictors of developing an infection, were in-
cluded in the Poisson regression model according to
univariate results and clinical considerations. Adjusted
robust IRR and confidence intervals were calculated using
an extra-Poisson variation regression model. Compared to
the usual Poisson regression model, this gives the same
estimates but wider confidence intervals (through greater
standard errors). All analyses were performed using Stata
(Stata College Station, TX version 8).
Results
Demographic and clinical characteristics of patients and
infection rates are reported in Table 1. The patientsprovided a total of 911.8 patient-years of follow-up, with a
median follow-up time of 26.04 months (interquartile
range 13.77 to 47.28), in particular 21.4% of patients were
followed for 12 months or less and 23.2% for more than
48 months. One-hundred and seventy-six (52%) patients
had at least 1 infection, the total infections being 331
(96.1% non-serious versus 3.9% serious; mean infections/
patient 1.9, range 1–8).
The infection rate in the first 6 months of treatment
was 3.8 per 100 patient-months, and in the subsequent
semesters was 3.3, 3.3, 2.7 and 3.0. The chi squared test
for the comparison of the semesters and the test for
trend are not statistically significant.
The difference between the rates for males and females
was statistically significant, females being at increased
risk. There was a tendency for the rate to decrease with
increasing age-group, but this was not statistically sig-
nificant. The rates for the two types of diseases, RA and
SpA, were similar. The rate increased with disease activ-
ity, especially for the “moderate” and “severe” categories;
however the very low rate observed for the “mild” group
was based on few cases. The risk showed a decreasing
trend with disease duration, but this was not statistically
significant. Vaccination against influenza and the ab-
sence of comorbidities tended to reduce the infection
rates, but these were not statistically significant at the
5% level.
The sites and types of non-serious and serious infec-
tions are reported in Table 2. One male patient under
anti-TNFα + CS therapy died from pneumonia of pre-
sumed viral etiology, whereas no other mortality or per-
manent sequelae were observed as a consequence of
infections. Moreover, 16/229 (7%) anti-TNFα-treated pa-
tients were positive at TST screening, without radio-
logical and/or microbiological tubercular findings. All of
them underwent prophylactic treatment two months be-
fore starting biologics and no tuberculosis reactivation
was observed in the follow-up. Finally, no HBV surface
antigen positivity was found, whereas HBV core anti-
bodies were positive in 12% of patients; all were investi-
gated for HBV viremia with negative results, and thus
they were considered potential occult HBV carriers [25].
No HBV reactivation was observed in these patients dur-
ing the follow-up. Three observed HCV positive cases,
one of whom also positive for viremia, were treated with
biologics (the patient with viremia only after a pegylated
interferon and ribavirin three-month treatment course),
without viral reactivation.
The IR/100 patient-years for all infections was 36.3 (95%
CI from 32.4 to 40.3), but it was higher in the presence of
anti-TNFα therapy than with DMARDs alone (the control
or reference group) or with CS, as reported in Table 1.
When anti-TNFα therapy was combined, especially with
CS, the infection risk significantly increased. DMARDs
Table 1 Demographic and clinical characteristics of patients and crude infection rates/100 patient-years according to











Patients N 30 82 24 42 42 121 341
Gender
Male 8 15 12 13 11 34 93
Female 22 67 12 29 31 87 248
Age
<50 9 15 12 17 14 38 105
50-59 9 22 3 7 8 29 78
60-69 5 22 6 4 13 34 84
≥70 7 23 3 14 7 20 74
Type of disease
RA 9 64 8 29 23 90 223
SpA 21 18 16 13 19 31 118
Disease duration
<5 years 21 41 7 6 14 28 117
5-9 years 2 29 3 18 11 43 106
≥10 7 12 14 18 17 50 118
Vaccination for influenza
Yes 5 24 4 18 17 57 125
No 25 58 20 24 25 64 216
Comorbidities and smoking
Yes 13 24 17 16 21 55 146
No 17 58 7 26 21 66 195
All infections N 7 29 16 70 43 166 331
Serious infections N 0 0 1 2 2 8 13
Patient-years 49.2 233.5 52.7 111.6 103.9 360.9 911.8
Infections /100 14.2 12.4 30.4 62.7 41.4 46.0 36.3
Patient-years
p value Reference group 0.721 0.09 0.00001 0.0039 0.0003 -
CS: Corticosteroids; DMARDs: Disease Modifying Anti-Rheumatic Drugs; TNF: Tumour Necrosis Factor.
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dose (10–15 mg/weekly and <10 mg/daily, respectively).
The IR/100 patient-years for serious infections was 1.4.
The adjusted results obtained from the Poisson regres-
sion are reported in Table 3. These results are broadly
similar to the crude comparisons. However, the adjusted
analysis implied a significant increase for females, a sig-
nificant decrease in the risk with increased duration of
the disease and influenza vaccination was significantly
protective towards infections, in particular towards skin
and soft tissue infections as shown in Table 4.
Discussion
In this study, an IR/100 patient-years of 36.3 was ob-
served for all infections in 341 RA and SpA patients,being 34.9 for non-serious and 1.4 for serious infections.
These results are similar to those reported from the
CORRONA Register on a larger RA US patient population
(32/100 patient-years) [30], while other studies have re-
ported higher (48.2) [31] and lower rates (22.6, 28.3 and
6.8 for treatment with Etanercept, Infliximab and non bio-
logical DMARDs, respectively) [32]. For serious infections,
the rate observed in this study is generally lower than those
observed in other studies, excepting that in the COR-
RONA Register, where the IR was 0.8/100 patient-years for
hospitalized infections [30]. The IRs/100 patient-years
for serious infections are, in fact, higher in the German
Biologics Register (6.4, 6.2 and 2.3, for treatment with
Etanercept, Infliximab and non biological DMARDs, re-
spectively) [32] and in the British Register (5.3 and 4.1
Table 2 Site and type of non-serious and serious infections
Non-serious Serious Total
N (%) N (%) N (%)
318 (96.1) 13 (3.9) 331 (100)
Site of infection
Respiratory 120 (36.3) 7 (2.1) 127 (38.4)
Uro-genital 111 (33.5) 0 111 (33.5)
Skin and soft tissue 66 (20.0) 4 (1.2) 70 (21.2)
Gastrointestinal 21 (6.3) 0 21 (6.3)
Bone 0 2 (0.6) 2 (0.6)
Type of infection*
Bacterial* 236 (71.3) 12 (3.6) 248 (74.9)
Escherichia coli 40 (12.1) 0 40 (12.1)
Staphylococcus aureus 4 (1.2) 4 (1.2) 8 (2.4)
Proteus mirabilis 3 (0.9) 0 3 (0.9)
Klebsiella pneumoniae 2 0 2
Serratia marcescens 1 0 1
Yersinia spp 1 0 1
Chlamydia trachomatis 1 0 1
Viral* 61(18.4) 1 62 (18.7)
Herpes simplex 40 (12.1) 0 40 (12.1)
VZ virus 8 (2.4) 0 8 (2.4)
Fungal* 21 (7) 0 21 (7)
Candida albicans 5 (24) 0 5 (24)
Malassezia furfur 4 (19) 0 4 (19)
*It was not possible to identify micro-organism for all infections.
Table 3 Poisson regression incidence rate ratios
Crude IRR
Gender female vs male 1.26
Age (effect per 10 years) 0.88
Disease duration 5–9 vs <5 years 0.92
Disease duration 10+ vs <5 years 0.82
DMARDs + CS vs DMARDs^ 0.87
Anti-TNFα vs DMARDs^ 2.14
Anti-TNFα + CS vs DMARDs^ 4.42
Anti-TNFα + DMARDs vs DMARDs^ 2.92
Anti-TNFα + DMARDs + CS vs DMARDs^ 3.24
Presence of comorbidities* and smoking 1.22
Anti-influenza Vaccine 0.84
Moderate Disease Activity vs Mild at baseline 5.95
Severe Disease Activity vs Mild at baseline 11.29
SpA vs RA 0.91
*presence of at least one of the following comorbidities: COPD, diabetes and leuko
^DMARDs = control group.
COPD: Chronic Obstructive Pulmonary Disease; CS: Corticosteroids; DMARDs: Disease Mod
TNF: Tumour Necrosis Factor. IRR:Incidence Rate Ratio, CI: confidence interval.
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[19]. In a recently published multicenter retrospective
cohort study, RA patients had IRs 8.2 versus 7.8 for bi-
ologics versus non biological DMARDs, and for psoriasis/
spondyloarthropathy the rates were 5.4 versus 5.4 respect-
ively [10]. Moreover, an Italian RA population study [33]
reported an IR 3.6.
The percentage of patients infected among those treated
with DMARDs and biologics is seldom reported, but var-
ies from 13% [32], through 23% [30] and 34.5% [31], to
51% [34]. Among the cases described here, it is 176/341,
52% (146 [83%] of whom were treated with biologics and
111 [63%] of them also with CS in addition to biologics).
Despite the difficulty of providing an interpretation of this
variability, as proposed by Salliot et al. [31], the different
percentages of patients on CS and/or anti-TNFα therapies
may in part account for the observed variation. Indeed, in
the current study, the proportions of patients treated with
anti-TNFα (229/341 [67%]) or with CS (245/341 [72%])
(anti-TNFα and CS associated in 163/341 [48%]) are
higher than in other studies (45% and 24% respectively
in Au et al. [30]), but lower, for CS, than in the German
Biologics Register [32], where it was 82%.
Infections were mainly (> 90%) respiratory, uro-genital
or cutaneous/soft tissue, as found by others [31,32]. Skin
and soft tissue infections were considered important in
patients under anti-TNFα therapy even in 2006 [20,35],
probably as a consequence of the TNFα role in cutane-
ous immunity [36]. TNFα, in fact, is a key cytokine re-
sponsible for cutaneous endothelial activation and therebyAdjusted IRR 95% CI p
1.37 1.01 1.86 0.042
0.95 0.86 1.05 0.302
0.67 0.48 0.93 0.016
0.61 0.45 0.83 0.002
0.76 0.34 1.68 0.493
1.57 0.55 4.51 0.400
3.60 1.58 8.20 0.002
2.11 0.95 4.71 0.067
2.54 1.15 5.59 0.021
1.07 0.85 1.37 0.554
0.73 0.57 0.94 0.016
4.12 1.24 13.68 0.021
4.28 1.21 15.08 0.024
0.96 0.67 1.38 0.817
penia.
ifying Anti-Rheumatic Drugs; RA: Rheumatoid Arthritis; SpA: Spondyloarthropathies;
Table 4 Effect of influenza vaccination on respiratory, uro-genital, skin/bone/soft tissue and gastro-enteric infection risk
Site of infections Influenza vaccination Number of infections Patient-years of follow-up Rate p
Respiratory No 74 165.57 0.447
Yes 53 128.26 0.413 0.666
Uro-genital No 58 117.92 0.492
Yes 53 113.65 0.466 0.781
Skin/Bone/Soft tissue No 52 61.91 0.840
Yes 20 85.49 0.234 0.0001
Gastro-enteric No 13 28.09 0.463
Yes 8 29.84 0.268 0.229
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it is also important in the mobilization of cutaneous
antigen-presenting cells (Langerhans cells) from the epi-
dermis to draining lymph nodes [37,38] The virulence of
Staphylococcus aureus is confirmed, having been iso-
lated in over 30% of the serious infections. Contrary to
Favalli et al. [33], in this study there were no cases of
active tuberculosis, probably because the patients were
enrolled after 2001 [39], when sensitivity to possible tu-
bercular reactivation in anti-TNFα-treated patients be-
came very high. The percentage of HBV core antibody
positivity is lightly higher than, but not significantly dif-
ferent from, that reported by Caporali et al. (12% versus
9%) [40]. Lack of HCV reactivation in the three treated
patients is in line with the literature [28,41].
IRs/100 patient-years in the different patient groups
stratified according to treatment type range from 12.4
(DMARDs + CS), to 14.2 (DMARDs), to 30.4 (anti-
TNFα alone), to 41.4 (anti-TNFα + DMARDs), to 46.0
(anti-TNFα + DMARDs + CS) to 62.7 (anti-TNFα + CS).
Thus, CS behave as immunosuppressants when associated
with anti-TNFα, but are less influential when combined
with DMARDs, whereas biologics seem to be associated
with enhanced infection risk. In contrast to other authors
[10,42,43], we did not observe a temporary increase of in-
fection risk in the first period after start of immunosup-
pressive therapy.
The multivariate analysis shows that the type of dis-
ease (RA or SpA) does not significantly affect the infec-
tion risk (IRR 0.96), therefore the two patient groups
have been considered as a single population. This may
be probably due to a sort of “balancing” effect of im-
munosuppressive therapy on the different infection risk
of RA and SpA per se. Comorbidities have not been
found to significantly affect the infection risk (IRR 1.07),
but the confidence interval is wide (0.85-1.37). It would
be interesting to investigate the effects of the single co-
morbidities and combinations of them, but the sample
size is too small for an analysis of this type. However, in
females, the infection risk is increased by more than one
third, as already observed by Lacaille et al. [9] and by Auet al. [30]. Female gender as a pro-infective element may
be linked to the impact of uro-genital infections which
are more common in females [44]. Disease duration is
generally considered a risk factor for infections [19,45],
whereas in this study, surprisingly, it was protective. The
crude effects are not statistically significant, but disease
duration is very likely to be confounded with other
factors, for example age, the presence of comorbidities
and disease activity, and this may explain the increased
and statistically significant effect observed in the adjusted
analysis. Indeed, protection may be linked to the high
proportion (> 90%, data not shown) of patients with
mild-moderate disease activity during the follow-up
(patients with ≥ 2 years of treatment) as a consequence
of treatment effectiveness. Despite the limited evidence
regarding the impact of the disease activity on the sus-
ceptibility for infections [46], recently Au et al. found that
higher disease activity was associated with a higher prob-
ability of developing hospitalized infections [30]. In the
current study, baseline disease activity is closely associ-
ated with infection risk, with an IRR of 4.3 and 4.1
for severe and moderate versus mild disease activity,
respectively. Chronic inflammatory diseases and infections
are both interwoven with disease activity. High disease ac-
tivity, in fact, is the expression of chronic inflammatory
state, which in turn may suppress the immune system [47],
thus making the development of infectious diseases easier.
Conversely, infections may strongly stimulate the immune
system, thus enabling, through inflammation, the under-
lying disease to reactivate. Both processes are able to in-
crease the level of the indices for disease activity.
The most interesting results come from treatment
type. Anti-TNFα alone increases the IRR and when com-
bined with CS more than triples it compared with
DMARDs alone. Moreover, DMARDs seem to provide
protection against infection in patients taking biologics,
CS and DMARDs together, compared with biologics and
CS alone, the IRR being 2.5, instead of 3.6. In agreement
with recent studies, which have identified a significant risk
for non-serious [7-9,48] and serious [8-14,46,49-52] infec-
tions for even low-dose CS (< 10 mg/day of prednisone)
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thus likely immunosuppressive, especially if combined
with anti-TNFα. Moreover, the association CS/anti-TNFα
therapy has been recently described as strong predictor of
serious infections in RA [46,52,53]. Biologics were instead
associated with a net increased infection risk, mainly when
administered with CS. DMARDs (mainly MTX) appear to
be safer regarding infection risk, with an IR/100 patient-
years (12.9) comparable to that (12.87) observed by Doran
et al. [7] in non RA controls. The apparent lack of MTX
pro-infective action, or rather its possible protective effect,
has already been reported [9,19]. This may be partly re-
lated to its anti-methylenetetrahydrofolate reductase activ-
ity, which is able to inhibit bacterial [54] and viral [55,56]
proliferation. The important increase in the risk of in-
fection associated with the combined treatment CS +
anti-TNFα may instead be because CS, in addition to
the induction of apoptosis on T lymphocytes [57], are
able to reduce cytokine production [57]. This includes
TNFα which appears to be the most sensitive [58]. Anti-
TNFα therapy is only able to inactivate TNFα, which is
increased in RA patients, without effect on its synthesis.
This may, instead, be inhibited by CS [59]. Anti-TNFα
agents, on the other hand, may reverse the TNFα-
induced CS resistance in RA, by restoring the TNFα-
inhibited glucocorticoid receptor function [60,61]. The
CS/anti-TNFα combination, therefore, synergizes in lower-
ing TNFα levels through different and independent mecha-
nisms, with consequent enhanced anti-inflammatory effect,
but at the expense of a raised infection risk [52]. Physi-
cians, therefore, should be aware that there may be an in-
creased risk of infection, when using CS and anti-TNFα
therapy together. However, this result is not obtained from
a randomized clinical trial. There may be residual con-
founding due to factors which have not been included
in this study, which could explain the association be-
tween increased risk of infection and the combination
of CS and anti-TNFα therapy. Thus, the topic deservers
further studies.
As found by Schneeweiss et al., patients treated with
anti-TNFα were more likely to have received at least one
influenza vaccination [50]. Moreover, having been vacci-
nated at least once against influenza was found to be sig-
nificantly protective towards the overall risk of infection
in the multivariate analysis. This observation appears
important, but there are caveats. First, lack of solid
evidence of influenza vaccine efficacy in immunosup-
pressed populations [62,63]; second, the impossibility
to establish a correlation between vaccine administration
and protection from virologically confirmed influenza in
the same year; third, the finding that vaccination is pro-
tective against all infections, with varying IRR, but signifi-
cantly (p < 0.001) only for skin/bone/soft tissue infections.
However, although vaccination may be confounded withunrelated factors, such as compliance with long term
medication, or the preferential recruitment of patients
with mild/moderate disease activity among the vaccinees,
its effect should be reduced or eliminated in a regression
model which takes account of these factors. On the con-
trary, our results imply that the protective effect of vaccin-
ation is increased and remains statistically significant after
adjustment for these variables. The very low number of
ILI episodes (14 patients, 2 of whom vaccinated and 12
non vaccinated) may explain the lack of statistical signifi-
cance for ILI. Moreover, the high statistical significance
found for skin/bone/soft tissue infections, (the majority
of which were herpetic [> 55%]), may perhaps be
associated with a specific protective action. This obser-
vation is in agreement with Miller JB who in 1979 re-
ported that flu vaccine reduced discomfort produced by
both, influenza and herpes infections [64]. Furthermore,
it has recently been demonstrated that a significantly
higher anti-influenza response is induced by a plasmid
influenza nucleoprotein DNA vaccine combined with her-
pes simplex virus (HSV) viral protein 22 gene. This may
imply a high level of cross-induced anti-influenza protec-
tion by HSV antigen [65].
This study has potential limitations because it is a
retrospective analysis of observed clinical results. There
was no a priori consideration of sample size and power
because the patients included were those observed in
the Immuno-rheumatology Division during the selected
time period. However, it can be calculated that, although
the number of patients is relatively low, the study would
have had a power of more than 99% to detect the ob-
served difference between treatment with DMARDs + CS
and treatment with anti-TNFα + CS significantly at the 5%
level. The relatively small sample size may lead to some
real associations not being detected and confidence inter-
vals may be so wide as to include clinically important
values. Moreover, the low sample size may be offset by the
study being single-centre, thus eliminating inter-centre
variability, which may prevent under-ascertainment and/
or misclassification of infectious events or other clinical
information.
Another potential source of bias is inherent in the
design of the study. The patients included in the study
were those who attended the Immuno-reumathology
Clinic during a fixed period of time; that is, they were
prevalent cases (in the period) not incident. This may
have lead to a higher probability of inclusion for patients
with long duration of disease, that is patients with a bet-
ter prognosis. Given that the time interval for inclusion
was relatively long, six years, we believe this bias is unlikely
to have had a great effect on the conclusions regarding the
incidence of infections in the treatment groups.
A further limitation of the study is the lack of matching
among groups exposed to different therapeutic protocols
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of the study type. Moreover, the evaluation of infection risk
for RA and SpA patients together, has been performed fol-
lowing the non-significant comparison between RA and
SpA in the multivariate regression. It could be hypothe-
sized that immunosuppressive therapy may have balanced
the infection risk between the two different pathological
conditions. Finally, comorbidities have been analyzed as a
whole and not singularly because of the small number of
cases in each; this may miss some important effects and
may account for discrepancies observed with some litera-
ture data.
Conclusion
In conclusion, this study suggests a high pro-infective
potential of the combination of anti-TNFα agents and
CS, and provides a biological interpretation of the synergy.
According to EULAR [66] recommendations, CS should
be tapered as soon as possible. Indeed, our results suggest
that, even though CS may delay radiographic joint damage
[67], they should be used carefully with biologics. The
search for personalized treatment options should be
driven by these considerations, trying to maintain with
DMARDs the remission phases induced by biologics, as
indicated by EULAR [66]. The observed association be-
tween influenza vaccination and skin, bone, soft tissue in-
fections has never been described before, to the best of
our knowledge, is interesting, and deserves further study.
Thus this may represent a further rationale for the
already recommended administration of influenza vaccine
to these patients [68-70]. However, larger prospective stud-
ies analyzing the role of CS, non biological DMARDs and
single biologics on infection risk should be planned and
implemented, in order to give a definitive answer to the
question of the safety for the immune system of these
treatments and their cost effectiveness.
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